** Analysts at Morningstar maintain fair value estimates on Australian health companies, anticipating a change in U.S. President Donald Trump's position on pharmaceutical tariffs
** Trump said on Tuesday he plans to announce tariffs on imported pharmaceuticals to the U.S. which could reach 200%
** Investment research firm sees CSL CSL.AX being impacted by the tariffs as it processes some U.S. products in Australia, but doesn't expect earnings to take a material hit
** "Tariffs this high are unlikely to persist and CSL can adapt by onshoring manufacturing" - Morningstar
** Also anticipates Ansell ANN.AX, Polynovo PNV.AX, Nanosonics NAN.AX, and Fisher & Paykel FPH.NZ to be impacted, if tariffs come into effect
** Says Telix TLX.AX is enviably exempt from all potential tariffs on pharmaceuticals though shares remain overvalued
Morningstar Fair Value Estimates -
Stock | Fair Value Estimates |
CSL Ltd | A$325 |
Fisher & Paykel Healthcare | A$25 |
Ansell | A$36.50 |
A$19.50 | |
Nanosonics | A$4.30 |
Polynovo | A$1.15 |
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。